Halozyme Therapeutics (NASDAQ:HALO) Downgraded by ValuEngine

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday, ValuEngine reports.

HALO has been the subject of several other reports. Barclays reissued a “sell” rating and issued a $17.00 price objective on shares of Halozyme Therapeutics in a research note on Monday, August 12th. Cantor Fitzgerald increased their price objective on Halozyme Therapeutics from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, July 1st. BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Zacks Investment Research raised Halozyme Therapeutics from a “sell” rating to a “hold” rating and set a $18.00 price objective for the company in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $20.75.

Halozyme Therapeutics stock traded up $0.07 during mid-day trading on Monday, hitting $15.33. The company’s stock had a trading volume of 515,409 shares, compared to its average volume of 798,672. The firm’s 50 day moving average is $15.89 and its 200 day moving average is $16.22. The company has a market cap of $2.23 billion, a PE ratio of -27.38 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 2.57. Halozyme Therapeutics has a 52-week low of $13.24 and a 52-week high of $17.79.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The firm had revenue of $39.10 million during the quarter, compared to the consensus estimate of $42.94 million. Halozyme Therapeutics had a negative return on equity of 16.97% and a negative net margin of 23.53%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.16) EPS. As a group, analysts forecast that Halozyme Therapeutics will post -0.33 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtus ETF Advisers LLC raised its stake in shares of Halozyme Therapeutics by 1.2% during the 2nd quarter. Virtus ETF Advisers LLC now owns 51,461 shares of the biopharmaceutical company’s stock worth $884,000 after purchasing an additional 626 shares in the last quarter. Taylor Wealth Management Partners raised its stake in shares of Halozyme Therapeutics by 0.4% during the 2nd quarter. Taylor Wealth Management Partners now owns 205,084 shares of the biopharmaceutical company’s stock worth $3,523,000 after purchasing an additional 735 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Halozyme Therapeutics by 25.2% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 967 shares in the last quarter. NumerixS Investment Technologies Inc raised its stake in shares of Halozyme Therapeutics by 70.7% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 990 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in shares of Halozyme Therapeutics by 2.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 44,890 shares of the biopharmaceutical company’s stock worth $771,000 after purchasing an additional 1,050 shares in the last quarter. 82.57% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Story: What is Cost of Debt?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.